Expression of heparanase and angiopoietin-2 in patients with endometriosis

Cai Jingting, Jingting Cai, Zhang Yang-de, Zhang Yangde, Yi Zhang, Zhang Yi, Mengxiong Li, Li Mengxiong, Rong Yu, Yu Rong, Zhang Yu, Peng Guoqing, Peng Guo-qing, Peng Lixiu, Peng Li-xiu
European journal of obstetrics, gynecology, and reproductive biology · 2006 · vol. 136(2) , pp. 199–209 · doi:10.1016/j.ejogrb.2006.09.018 · PMID:17141400 · W2078056956
article OA: closed CC0 ⤵ 15 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated the expression of heparanase and angiopoietin-2 in endometriosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiopoietin-2 Endometriosis Endometrium Glucuronidase Adult Angiopoietin-2 Blotting, Western Case-Control Studies Endometriosis Endometriosis Endometriosis Endometrium Endometrium Endometrium Female Gene Expression Glucuronidase Heparanase Humans Menstrual Cycle

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (56)

Cited by (15)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:15:06.633332+00:00
License: CC0 · commercial use OK